Showing posts with label obesity. Show all posts
Showing posts with label obesity. Show all posts

Friday, February 18, 2011

Childhood Obesity Campaign: Issues in Health

UPDATE: 4 August, Sugar Cut in Cereals

Remember that most of the big name cereals have been loaded with high fructose corn syrup (HFCS) for years.  And also consider that it is the organic brands of cold, boxed cereal that is also loaded with sugar, only they use the organic kind.  Either way you look at it the sugar has to go, the HFCS has to go, and all of the cereals with any GMO grain or other ingredient - like beet sugar that now is about 100% of the market -) nneds to come out of these and any other product containing them.



3 February, 2010  Michelle Obama Kicks Off Childhood Obesity Drive
Mrs. Obama is taking on her first substantive policy role in overseeing the Obama administration programs and partnerships dealing with what is considered a national epidemic of childhood obesity.

http://www.politicsdaily.com/2010/02/01/michelle-obama-kicking-off-childhood-obesity-drive-feb-9/

My hope is that Michelle addresses the role of vaccines, fluoride, environment, lack of physical education in schools, the USDA food pyramid that promotes obesity, unhealthy school lunches, artificial sweeteners proven to cause obesity, HFCS, soy formula, microwave cooking, GMO soy and canola oil disguised as " plant sterols" and not healthy saturated fat, TV ads and cold cereals, and some of Tom Vilsack's GMO buddies, and more to be concerned with.  We are just a nation of starving children who are malnourished because of the focus of today's government guidelines.


Some 30+ related articles on obesity can be found here at Natural Health News

Originally posted  3/6/09

Somehow I think the lineal thinking process, or lack of any kind of meaningful thinking, is a very real issue as we address the needs for health care change and reform in the US, and of course in the world.

I also think that as long as we have this mind set those who see themselves as power brokers just might not be hitting the target, so to speak.

Try to put a few puzzle pieces together here as I give you food for thought.

First of all, look at the USDA. This is the place where dietitians get their basic education. Since most of this is funded by Big AG is it no wonder RDs end up on the short end when it comes to how this translates to a role in health care delivery. Remembering too that the ADA (American Dietetics Association) wants to control ALL nutrition education, and they support aspartame, sucralose (both known obesity promoters) and the faulty food pyramid.

Luise Light, PhD, the originator of the first food pyramid with real food, might give you more to think about. Her opinion of grains is certainly not the same as ADA or USDA or for that matter, Big AG.

Today, you can read about a culture of bias in ADA education. If it is found in students of dietetics (dietetics is not nutrition) then you can be sure it is in the faculty and the field as well.
Bias Against Obesity Is Found Among Future DietitiansBy Carolyn Colwell Healthday Reporter
Mar 5, 2009

THURSDAY, March 5 (HealthDay News) -- Just 2 percent of those training to be dietitians have positive or neutral attitudes toward people who are obese, and the rest are moderately biased against their prospective patients, a new study has found.

"Essentially, this shows that future dieticians are not immune to weight bias, and there are negative attitudes toward obese patients that may have a negative impact on the quality of care," said Rebecca Puhl, the study's lead author and the director of research and stigma initiatives at Yale University's Rudd Center for Food Policy and Obesity.

Most of the almost 200 dietetic students who participated in the study had pejorative views about the attractiveness, self-control, overeating, insecurity and self-esteem of people who are obese. They also rated obese patients as being less likely than non-obese patients to comply with treatment recommendations. The findings were published in the March issue of the Journal of the American Dietetic Association.

But the students aren't alone in their beliefs and share the biases with other health-care providers, Puhl said, adding that other studies have shown that many health professionals have negative perceptions about very overweight patients. Patients have reported "very many examples of providers who really make very stereotypical comments that suggest that they are making assumptions about a patient's character, intelligence or abilities because of their weight," she said.

Other signs of professional insensitivity, Puhl said, include weighing obese patients on freight scales because scales in a doctor's office don't accommodate their weight and not having blood pressure cuffs big enough for a heavy patient.

She said that the attitudes expressed by the dietetic students in the study show a lack of appreciation for how difficult it is to lose weight and for the biological factors involved. Also, the message that obesity results from a lack of self control ignores mounting scientific evidence that it's difficult to lose weight and keep it off for a sustained period of time, she said.

"Most people, when they walk into an office, have already tried to lose weight and, more likely, they've lost weight and regained the weight," Puhl said. "I think a better understanding and appreciation of the complexities and difficulties of weight loss are needed to reduce the stigma."

The 182 students who completed the study were from 14 universities and had been enrolled in an undergraduate dietetics program for about two years. With an average age of 23, 92 percent were women, and 85 percent were white.

The researchers asked the students to respond to questions about a normal-weight male and female and an obese male and female. The people they were asked about shared the same health characteristics except for weight.

Dr. Nicholas H.E. Mezitis, an assistant professor of clinical medicine and nutrition at Columbia University College of Physicians and Surgeons, said that the findings might be misleading because of the small number of minority students and the predominance of white females among the participants. "If you get into ethnic communities, such as a black population, they all have different views," he said. In some groups, he explained, being thin might not be seen as desirable.

"We also have to bear in mind that a lot of what these students are reading in magazines and such are taking them to the other extreme," Mezitis said. "What's desirable is very thin, and … these [obese] patients are way on the other extreme."

Lona Sandon, a spokeswoman for the American Dietetic Association, added that students' mentors need to provide positive role modeling. "If mentors reflect weight bias, then students are likely to do the same," she said. "In addition, one's own attitudes about body image may influence attitudes towards other's weight."

The study recommends adding stigma reduction to the standard curriculum for dietetics programs. The Obesity Society has more on weight-related bias.

Then we have to give some attention to this announcement of the joint venture between the heart association (AHA), Nickelodeon and Bill Clinton's organization to allegedly fight childhood obesity.

Then consider the Healthy School Lunch Program and what actually took place over a decade ago in Wisconsin, and you have to wonder about why all of this has been taking so long.

Then remember when the push started for the Hepatitis B vaccine? It was pretty clearly established that no long term studies had been done with this vaccine, and it contributed to the development of diabetes and some other scary for parents kinds of issues.

Then, if you recall history, Mr. Bill awarded the developers of the Hepatitis B vaccine the National Technology Award.

Is it guilt, is it greed, or is it that there is a real interest in change this issue for our children.

One has to ask because we haven't seen a response on aspartame even though the FDA knows it causes diabetes and obesity.

And certainly there has to be consideration of cultural concerns because in the American Indian and other ethnic and forgotten communities, nuttrition, diabetes and weight issues are major public health problems.

Now you have some real food for thought.

Tuesday, January 11, 2011

Do Diet Drugs Drop Density

Not sure if its the AP writer or Arena Pharmaceuticals that wants you to take a bit of this one with a veil of success.  I'm skeptical so far because I've looked at the statistics. Their PR says 13 percent to 15 percent of body weight, but is you read the reports it takes about a year to reduce by very few percentage of pounds.

And there are risks as well as problems related to monkeying with your serotonin.

"Lorcaserin works in a way similar to fenfluramine, which was part of the fen-phen diet cocktail before it was withdrawn in 1997 after being linked to heart valve damage."
http://www.reuters.com/article/idUSN1225473220100312

Fenfluramine is a fluoride based compound with benzene
http://naturalhealthnews.blogspot.com/2010/07/common-sense-needed-not-new-risky.html
Lorcaserin 10 mg Once Daily
40.2% of patients treated with 10 mg of lorcaserin dosed once daily lost
at least 5% of their body weight (p<0.0001); and
17.4% of patients treated with 10 mg of lorcaserin dosed once daily lost
at least 10% of their body weight (p<0.0001).
 
Taking the drug twice daily (BID) increases your risk of serious side 
effects and you show little difference in weight loss over taking the drug
once daily
22.6% of patients treated with 10 mg of lorcaserin dosed twice daily
lost at least 10% of their body weight compared to 9.7% for placebo
(p<0.0001)
 
So for what costs you incur for the drug, price data which so far I haven't
located, you really aren't making signnificant progress.
 
If you weigh 250, in a year on this drug you may lose 12.5 - 25 pounds. And if
you follow a sound weight management plan without drugs and include exercise
you can safely look at a loss of 2 pounds a week.
Experimental diet pill shows promise, little risk
ATLANTA – An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.
Complete article/http://news.yahoo.com/s/ap/20100715/ap_on_he_me/us_med_obesity_drugs

http://invest.arenapharm.com/releasedetail.cfm?ReleaseID=410040
http://www.reuters.com/article/idUSN1225473220100312http://weightloss.suite101.com/article.cfm/will_new_weightloss_drug_make_it_to_market

There might be better ways to look at this health problem.

Thursday, December 30, 2010

Common Sense Needed, not new risky weight loss drug

Obesity Concerns Not Cured by A Risky Drug: FDA Plans to Review First of 3 New Diet Drugs

Remember Phen-Fen, an older alleged weight loss drug that harmed the hearts of many and often caused pulmonary hypertension among its other gifts?

It may be reappearing in a different form, a new concoction of phentermine and topiramate, ready to be reviewed by our trusting folks at the FDA.

Phen-Fen: The once-popular diet-drug combination of fenfluramine and phentermine that, amidst much media attention, was taken off the market because of concern for heart valve damage.
Fenfluramine hydrochloride is an anorectic drug for oral administration. Immediate release tablets containing 20 mg fenfluramine hydrochloride are orange, scored, compressed tablets engraved AHR and 6447.
Inactive Ingredients: Corn Starch, FD&C Yellow 6, Magnesium Stearate, Microcrystalline Cellulose, Silicon Dioxide, Sodium Lauryl Sulfate.
Fenfluramine HCl - one of many fluoride based drugs - has the following chemical name: N-ethyl-alpha-methyl-3-(trifluoromethyl) benzeneethanamine hydrochloride.
The most common adverse reactions of fenfluramine are drowsiness, diarrhea, and dry mouth. Less frequent adverse reactions reported in association with fenfluramine are:
    Central nervous system: Dizziness; confusion; incoordination; headache; elevated mood; depression; anxiety, nervousness, or tension; insomnia; weakness or fatigue; increased or decreased libido; agitation, dysarthria. Gastrointestinal: Constipation; abdominal pain; nausea. Autonomic: Sweating; chills; blurred vision. Genitourinary: Dysuria; urinary frequency. Cardiovascular: Palpitation; hypotension; hypertension; fainting; pulmonary hypertension. Skin: Rash; urticaria; burning sensation. Miscellaneous: Eye irritation; myalgia; fever; chest pain; bad taste.
Drug Abuse and Dependence
Fenfluramine hydrochloride is a controlled substance in Schedule IV. Fenfluramine is related chemically to the amphetamines, although it differs somewhat pharmacologically.

Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethyl sulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solu tion has a pH of 6.3. Topiramate has the molecular formula C
12H21NO8S and a molecular weight of 339.36. Topiramate is designated chemically as 2,3:4,5-Di-O-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula: used for Seizure and Migraine

14 July, 2010  NEW YORK (AP) – Vivus Inc.'s potential weight loss drug Qnexa will likely draw scrutiny over nervous system and psychiatric side effects from a panel of Food and Drug Administration experts this week.
But shares jumped in morning trading as the FDA acknowledged the potential blockbuster drug's effectiveness in cutting weight. The stock rose $1.75, or 16 percent, to $12.40 in morning trading, more than doubling from a low of $5.57 last July.
The FDA raised some concerns in briefing documents posted online on Tuesday about a range of side effects. It said reviewers should take into account rates of depression, memory and concentration lapses, and heart-related issues, among others. The concerns were not a surprise to Wall Street, which has been following development of the drug over the last several years. Complete article
Side effects include but may not be limited to
Cardiovascular: Primary pulmonary hypertension and/or regurgitant cardiac valvular disease (see WARNINGS), palpitation, tachycardia, elevation of blood pressure.

Central Nervous System: Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache; rarely psychotic episodes at recommended doses.
Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.
Allergic: Urticaria.
Endocrine: Impotence, changes in libido.
Sensible responses to weight issues are welcome.
Our main organization, CHI, offers nutritional and spiritual counseling 
 
If the 'Phen' proportion isn't bad enough consider the anti-seizure drug's problems. Just check out page three of this drug information database and evaluate for yourself.





Sunday, December 12, 2010

PhRMA GREED leads to statins for children

Statins for children 10 to 17 have been FDA approved since 2002.  Now Pfizer seeks EU authorization. 
READ IT HERE FIRST: THE IMPORTANT ISSUES FACING YOU IN HEALTH CARE AT NATURAL HEALTH NEWS DAYS, AND OFTEN WEEKS OR MONTHS, AHEAD OF THE SITES THAT HAVE BEEN COPYING OUR WORK FOR MORE THAN 10 YEARS...
Liptor and other statin drugs already have a record of serious side effects and other problesm related to increased risk of demthia and cancer as well as liver and kidney failure.

At what price do those on the take at FDA, and in Congress, begin to show a little ethical behavior as well as really determining the root cause of why children are becoming obese.

Pfizer gets EU approval for kids' cholesterol drug

By LINDA A. JOHNSON, AP Business Writer  Tue Jul 6,  2010
TRENTON, N.J. – The European Union has approved a new chewable form of cholesterol blockbuster Lipitor for children 10 and up with high levels of bad cholesterol and triglycerides, a type of blood fat, Pfizer said Tuesday.
The approval includes children whose high blood fats are due to an inherited disease that causes extremely high cholesterol levels, familial hypercholesterolemia.
New York-based Pfizer Inc. won U.S. approval for Lipitor use in children 10 to 17 with that condition in 2002.
Lipitor is the world's top-selling drug, with 2009 sales of about $13 billion, but its U.S. patent expires at the end of November 2011. Pfizer, the world's biggest drugmaker, will quickly lose most Lipitor revenue once generic competition hits, so the company has been trying to boost sales where possible before then.
Pfizer said last fall that it plans to apply for a six-month extension of its patent in European countries, after doing studies of Lipitor in youngsters.
As in the United States, the European Union allows drug makers to seek an additional six months of patent protection for medications if they test them in children, who generally are excluded from the drug studies performed to win approval for a new medication.
Pfizer already won such an extension for its crucial U.S. patent on Lipitor.
For blockbuster drugs, those extensions can easily bring hundreds of millions of dollars in additional revenue. Normally, they are for drugs that are widely used by different age groups.
Until recently, cholesterol drugs have been primarily taken by adults with heart disease, but their use has expanded to younger patients as more obese, sedentary teenagers and adolescents develop heart disease and diabetes.
Lipitor is approved to lower risk of heart attack and stroke, but can cause dangerous muscle pain or weakness, and it cannot be taken by patients with liver problems or by nursing or pregnant women.

Monday, November 1, 2010

Clear association between obesity and vitamin D deficiency

Calcium, parathyroid health, and obesity

More on a study conducted at Uppsala University has demonstrated that obese people often suffer from serious vitamin D deficiency and poor calcium metabolism. The findings have been published in the Journal of Clinical Endocrinology and Metabolism. According to the researchers, the problem is under appreciated by the health care establishment.

Thursday, October 14, 2010

Better than BMI

Figuring out whether your weight is in the healthy range involves multiplication, division and calculating your height in inches, squared. If you do all that right, you'll get your Body Mass Index (BMI), which ideally should be in the range of 19 to 24.
Currently the BMI has been sidelined in favor of waist circumference measurements as being a better tool.
Now comes the revision of an old tool I used decades ago when I was in college and studying nutrition for health.
A Nevada professor of applied statistics has come up with an easier formula you probably can do in your head. 
Here's how: for women, the baseline height is 5 feet and the maximum weight limit (MWL) is 125, meaning that if you're 5 feet tall and weigh more than 125 you’re over your MWL. If you're taller, add 4.5 pounds for every extra inch so if you’re 5'5", your MWL would be 147.5 (125 + 22.5). If you’re less than 5 feet tall, subtract 4.5 pounds for every inch below that baseline. 
For men, the baseline height is 5'9" and MWL is 175. For every additional inch, add five pounds (or subtract five for every inch under 5'9"). Results closely correspond to your BMI. 
Professor George Fernandez presented his new method at the Sept. 22, 2009 Nevada Public Health Association Conference.

Friday, September 3, 2010

Finally, science agrees with herbalYODA on fructose

Food sweetener could be 'fuelling' childhood diabetes, study finds


The sweetener fructose, a cheap sugar substitute found in thousands of processed foods and soft drinks, may be increasing childhood diabetes and the obesity crisis, new findings suggest.


Fructose


By Amy Willis, Daily Telegraph, 13 Dec 2009

In a study by researchers at the University of California, 16 volunteers were put on a controlled diet with high-levels of fructose – a sweetener derived from corn.

After 10 weeks, the volunteers had developed more fat cells around the heart, liver and other major organs as well as showing signs of food processing abnormalities linked to diabetes and heart disease.

Another group of volunteers, who were also on a controlled diet but without the fructose, did not show the fat cell increase or the food processing abnormalities.

Both groups put on the same amount of weight.

Children are said to be in a higher risk group as they are more likely to eat products with high-levels of sweeteners over longer periods of time.

"This is the first evidence we have that fructose increases diabetes and heart disease independently from causing simple weight gain," Kimber Stanhope, a molecular biologist who led the study, told a Sunday newspaper.